Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13577
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGhabrial, Hanyen
dc.contributor.authorSewell, Richard Ben
dc.contributor.authorSmallwood, R Aen
dc.contributor.authorMorgan, Denis Jen
dc.date.accessioned2015-05-16T03:27:31Z
dc.date.available2015-05-16T03:27:31Z
dc.date.issued1998-02-01en
dc.identifier.citationClinical and Experimental Pharmacology & Physiology; 25(2): 110-3en
dc.identifier.govdoc9493498en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13577en
dc.description.abstract1. A 50 microL bolus dose containing (+/-)-propranolol hydrochloride (200 microg) and [14C]-sucrose, or antipyrine (2 mg) and [14C]-sucrose, or [14C]-taurocholate sodium was injected into the portal vein of the isolated perfused rat liver preparation and perfusate outflow samples were collected frequently for the next 30 min. After a 20 min washout period this procedure was repeated. 2. [14C]-Sucrose, antipyrine and [14C]-taurocholate each eluted as a single peak at 18, 31 and 28 s, respectively, after each dose. In contrast, propranolol eluted with two peaks at approximately 18 and 128 s after dosing. 3. There was no significant difference in dose-corrected area under the outflow curve (AUC) for [14C]-sucrose, antipyrine or [14C]-taurocholate between the first and second doses whereas the mean propranolol AUC for the second dose was only 0.577+/-0.439 that for the first dose (P<0.05). 4. Unmetabolized propranolol accounted for more than 80% of the drug in hepatic tissue for the first and second doses at 18 s and greater than 50% at 128 s, and there was no significant difference in these values at each time between the first and second doses. 5. These findings suggest that for an avidly extracted drug, such as propranolol, systemic availability of orally administered drug will be highly dependent on factors that influence the hepatic tissue binding of the drug.en
dc.language.isoenen
dc.subject.otherAdrenergic beta-Antagonists.pharmacokinetics.pharmacologyen
dc.subject.otherAnimalsen
dc.subject.otherArea Under Curveen
dc.subject.otherBiological Availabilityen
dc.subject.otherChromatography, High Pressure Liquiden
dc.subject.otherIn Vitro Techniquesen
dc.subject.otherLiver.drug effects.metabolismen
dc.subject.otherMaleen
dc.subject.otherPropranolol.pharmacokinetics.pharmacologyen
dc.subject.otherRatsen
dc.subject.otherRats, Sprague-Dawleyen
dc.titleA priming dose of propranolol reduces the availability of a subsequent dose in the isolated perfused rat liver preparation.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical and Experimental Pharmacology & Physiologyen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin, Australiaen
dc.description.pages110-3en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/9493498en
dc.type.austinJournal Articleen
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Feb 7, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.